U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the last session and the average volume of the stock remained 3.20million shares. The beta of the stock remained 0.88. Celgene Corporation (NASDAQ:CELG) insider ownership is 0.20%.

Arena Pharmaceuticals Inc (NASDAQ:ARNA) saw some unusual options trading activity on Friday. Investors purchased 18,110 call options on the company, AmericanBankingNews.com reports. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -2.54 percent to $6.15 Friday on volume of 9.85million shares. The intra-day range of the stock was $6.03 to $6.35. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $1.35billion.

Cell Therapeutics Inc (NASDAQ:CTIC) CEO James A. Bianco sold 395,000 shares of Cell Therapeutics Inc (NASDAQ:CTIC) stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $3.83, for a total transaction of $1,512,850.00. Cell Therapeutics Inc (NASDAQ:CTIC)’s stock on Mar 21, 2014 reported a decrease of -1.55% to the closing price of $3.81. Its fifty two weeks range is $0.97-$4.25. The total market capitalization recorded $570.142million. The overall volume in the last trading session was 9.95million shares. In its share capital, CTIC has 131.13million outstanding shares.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) is heading towards an important event as mentioned by its CEO Dr. Joseph Kim during the earnings call, which took place on Monday. This event relates to the company’s mid-stage data readout for its lead clinical candidate, VGX-3100, which is considered as a potential vaccine for HPV-caused cancers and pre-cancers. On Friday, shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -2.89% to close the day at $3.69. Company return on investment (ROI) is -68.30% and its monthly performance is recorded as 27.24%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) quarterly revenue growth is 71.63%.